Identification of Human Monoclonal Antibodies Specific for Human SOD1 Recognizing Distinct Epitopes and Forms of SOD1

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Broering, Teresa J ^a,b   Wang, Hongyan ^a   Boatright, Naomi K ^a   Wang, Yang ^a   Baptista, Katherine ^a   Shayan, Gilda ^a,c   Garrity, Kerry A ^a,d   Kayatekin, Can ^a,e   Bosco, Daryl A ^a   Matthews, C Robert ^a   Ambrosino, Donna M ^a,f   Xu, Zuoshang ^a   Babcock, Gregory J ^a,f  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b AbVitro Inc   (United States)

^c BIOGEN   (United States)

^d BLUEBIRD BIO   (United States)

^e WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^f VISTERRA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; EDETIC ACID; EPITOPE; HUMAN MONOCLONAL ANTIBODY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ENZYME STABILITY; ENZYME STRUCTURE; HIGH TEMPERATURE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOTHERAPY; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN ISOLATION; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; EPITOPES; HEK293 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOPRECIPITATION; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; SUPEROXIDE DISMUTASE;

MUS MUSCULUS;

EID: 84876218569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061210     Document Type: Article

References (47)

1. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344: 1688 1700.
2. Bensimon G, Lacomblez L, Meininger V, (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585-591.
3. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
4. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245-256.
5. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268.
6. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, et al. (1997) Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 41: 210-221.
7. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, et al. (2010) Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 13: 1396-1403.
8. Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, et al. (2012) An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A 109: 5074-5079.
9. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, et al. (2010) Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 5: e11552.
10. Brotherton TE, Li Y, Cooper D, Gearing M, Julien JP, et al. (2012) Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A 109: 5505-5510.
11. Strange RW, Antonyuk SV, Hough MA, Doucette PA, Valentine JS, et al. (2006) Variable metallation of human superoxide dismutase: atomic resolution crystal structures of Cu-Zn, Zn-Zn and as-isolated wild-type enzymes. J Mol Biol 356: 1152-1162.
12. Vande Velde C, Miller TM, Cashman NR, Cleveland DW, (2008) Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci U S A 105: 4022-4027.
13. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, et al. (2001) Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933-941.
14. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, et al. (2006) Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 9: 108-118.
15. Rothstein JD, (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65Suppl 1: S3-9.
16. Chattopadhyay M, Valentine JS, (2009) Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal 11: 1603-1614.
17. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.
18. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105-1116.
19. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327-338.
20. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11: 38-45.
21. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann of Neurol 39: 147-157.
22. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9: 4-15.
23. Urushitani M, Ezzi SA, Julien JP, (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 104: 2495-2500.
24. Takeuchi S, Fujiwara N, Ido A, Oono M, Takeuchi Y, et al. (2010) Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 69: 1044-1056.
25. Liu HN, Tjostheim S, Dasilva K, Taylor D, Zhao B, et al. (2012) Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J Neurosci 32: 8791-8799.
26. Gros-Louis F, Soucy G, Lariviere R, Julien JP, (2010) Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 113: 1188-1199.
27. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, et al. (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83: 12473-12482.
28. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, et al. (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74: 6339-6347.
29. Lonberg N, (2005) Human antibodies from transgenic animals. Nat Biotechnol 23: 1117-1125.
30. Wilcox KC, Zhou L, Jordon JK, Huang Y, Yu Y, et al. (2009) Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis. J Biol Chem 284: 13940-13947.
31. Kayatekin C, Zitzewitz JA, Matthews CR, (2008) Zinc binding modulates the entire folding free energy surface of human Cu,Zn superoxide dismutase. J Mol Biol 384: 540-555.
32. Svensson AK, Bilsel O, Kondrashkina E, Zitzewitz JA, Matthews CR, (2006) Mapping the folding free energy surface for metal-free human Cu,Zn superoxide dismutase. J Mol Biol 364: 1084-1102.
33. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, et al. (2005) An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem 92: 362-367.
34. Wang H, Ghosh A, Baigude H, Yang CS, Qiu L, et al. (2008) Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem 283: 15845-15852.
35. Kayatekin C, Zitzewitz JA, Matthews CR, (2010) Disulfide-reduced ALS variants of Cu, Zn superoxide dismutase exhibit increased populations of unfolded species. J Mol Biol 398: 320-331.
36. Grad LI, Guest WC, Yanai A, Pokrishevsky E, O'Neill MA, et al. (2011) Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc Natl Acad Sci U S A 108: 16398-16403.
37. Lang L, Kurnik M, Danielsson J, Oliveberg M, (2012) Fibrillation precursor of superoxide dismutase 1 revealed by gradual tuning of the protein-folding equilibrium. Proc Natl Acad Sci U S A 109: 17868-17873.
38. Kerman A, Liu HN, Croul S, Bilbao J, Rogaeva E, et al. (2010) Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol 119: 335-344.
39. Galaleldeen A, Strange RW, Whitson LJ, Antonyuk SV, Narayana N, et al. (2009) Structural and biophysical properties of metal-free pathogenic SOD1 mutants A4V and G93A. Arch Biochem Biophys 492: 40-47.
40. Banci L, Bertini I, Boca M, Calderone V, Cantini F, et al. (2009) Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. Proc Natl Acad Sci U S A 106: 6980-6985.
41. Svensson AK, Bilsel O, Kayatekin C, Adefusika JA, Zitzewitz JA, et al. (2010) Metal-free ALS variants of dimeric human Cu,Zn-superoxide dismutase have enhanced populations of monomeric species. PLoS One 5: e10064.
42. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, et al. (2004) Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 279: 15499-15504.
43. Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, et al. (2007) An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med 13: 754-759.
44. Forsberg K, Andersen PM, Marklund SL, Brannstrom T, (2011) Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol 121: 623-634.
45. Delrieu J, Ousset PJ, Caillaud C, Vellas B, (2012) 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 120Suppl 1: 186-193.
46. van Blitterswijk M, Gulati S, Smoot E, Jaffa M, Maher N, et al. (2011) Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12: 430-438.
47. Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, et al. (2012) Aberrant Localization of FUS and TDP43 Is Associated with Misfolding of SOD1 in Amyotrophic Lateral Sclerosis. PLoS One 7: e35050.